Abstract
Gastric cancer is the second most common cause of cancer-related deaths worldwide and poses a major clinical challenge due to limited treatment options. Fluoropyrimidine and platinum-based combination chemotherapy is the first-line standard of care in patients with locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Despite improved chemotherapy regimens, outcomes remain poor and survival is low. New therapies have focused on targeting the immune system, including the programmed death-1 receptor/programmed death-ligand 1 (PD-1/PD-L1) axis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
